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Introduction 
The practice of medicine has traditionally been devoted to healing and 
improvement of health by the prevention, cure, and management of 
disease. In recent years, this goal has been obscured with the widespread 
practice of surgical abortion-on-demand and the use of drugs and devices 
which cause destruction of the unborn baby (embryo or fetus). 
The prescribing of abortifacient drugs and devices by physicians 
conflicts with the generally accepted code of medical ethics, as outlined in 
the Hippocratic Oath: I 
50 
I will neither give a deadly drug to anybody if asked for it , nor will I make a 
suggestion to this effect. Similarly, I will not give to a woman an abortive remedy. 
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Since abortifacient drugs and devices carry a federal legend, i.e., 
"prescription only," the pharmacist has become linked to the dispensing of 
drugs which cause death of the unborn child. 
This paper reviews the currently marketed and investigational 
abortifacient drugs and devices and discusses the impact ofthese drugs and 
devices on health care personnel. 
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Figure I . The process of becoming pregnant (Reprinted with permission. Kippley. J. and S. 
The Art of Natural Family Planning, ed. 3. Couple to Couple League. Cincinnati. 1984) 
Basic Reproductive Physiology 
Figure I presents a simplified view of the female internal reproductive 
organs. 
Eggs , or ova, develop in ovarian follicles for release approximately once 
a month , in a process called ovulation. Most women release only one egg 
per cycle. After ovulation the ovum travels from the ovary into the 
Fallopian tube. If sexual intercourse (coitus) has occurred , the sperm 
travel through the opening of the uterus, the cervix, through the uterus and 
into the Fallopian tubes, where fertilization of the ovum occurs. 
Following ovulation the ovarian follicle becomes the corpus luteum 
(Latin, "yellow body") and secretes the hormone progesterone. 
Progesterone maintains the lining of the inner wall of the uterus, the 
endometrium, in preparation for pregnancy. If the egg has been fertilized 
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with sperm, it implants in the endometrium five to nine days following 
fertilization. The fertilized egg then produces a hormone called Human 
Chorionic Gonadotropin (HCG) which stimulates the corpus luteum to 
contjnue producing progesterone, thus preventing the sloughing of the 
endometrium in menstruation. (HCG is the substance which is detected in 
most pregnancy tests .) This HCG-stimulated production of progesterone 
by the corpus luteum will continue for several months, until the placenta 
begins production of progesterone. 
Abortifacient Drugs and Devices 
1. Sodium Chloride 20% (Abbott) 
This preparation of hypertonic saline is used to induce fetal death and 
abortion during the second trimester, preferably 16-22 weeks gestation.2 
The saline is administered through a large needle which is inserted 
through the abdominal wall of the mother into the baby's amniotic sac. 
Praior to injection ofthe hypertonic saline, amniotic fluid is removed, and 
an equivalent volume of saline is replaced into the amniotic sac ("saline 
amniocentesis"). Over the next several hours the baby breathes and 
swallows the saline, is poisoned , which results in struggling and sometimes 
convulsions ofthe baby. About 24 hours after administration of the saline, 
the mother usually begins labor and will deliver a dead baby) 
This method of abortion is sometimes termed "salt poisoning" abortion, 
due to the mechanism of action of the chemical. Acute hypernatremia, or 
salt poisoning, with generalized vasodilation, edema, congestion, 
hemorrhage, and shock lead to the death of the baby.4 Additionally, the 
corrosive salt solution often burns the baby's skin, resulting in the outer 
skin layers being stripped away. 
Extrapolation of Centers for Disease Control figures indicates that 
approximately 22,000 saline induced abortions were performed annually 
in the United States in the few years preceding 1983.5 However, the sole 
producer of 20% saline, Abbott Laboratories, has recently ceased 
production of this product. 6 Some feel that this decision is the result of 
boycotts of Abbott's monoclonal antibody pregnancy tests by over 2,000 
independent pro-life crisis pregnancy centers, e.g., Heartbeat, Birthright 
(USA), and those operated by the Christian Action CounciJ.7 
2. Prostaglandins 
This class of autacoids is one of the most ubiquitous in the body, with a 
wide variety of physiological actions on various tissues and systems. Of 
interest here are the effects which prostaglandins exert on the uterine 
musculature, specifically those found most abundantly in the uterus, 
menstrual, and amniotic fluid , the E and F types (PGE2 and PGFs). 
The uterine musculature in the pregnant woman becomes more 
responsive to the contractile stimulating properties of PGE2 and the PG Fs. It 
is also known that in the pregnant woman the prostaglandin concentrations 
rise in maternal and umbilical cord blood, and in amniotic fluid. 8,9 
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Unfortunately, these naturally occurring substances (prostaglandins) 
which have the physiological purpose to facilitate the birth of a baby, can 
also be used medically to kill the same baby by abortion. 
The prostaglandin preparations with the licensed indication for use in 
mid-trimester abortion are carboprost tromethamine, dinoprost trometha-
mine, and dinoprostone , all manufactured by Upjohn. 
Carboprost tromethamine (PROSTIN / 15 M; name changed to HE MA-
BATE in December, 198810) is a solution containing 0.25 mg of carboprost 
(I5-methyl PG F2a) per ml for intramuscular injection and is recom-
mended for abortion at 13-20 weeks gestation, or for refractory 
postpartum uterine bleeding. Dinoprost tromethamine (PROSTIN F2 
ALPHA) is a solution containing 5 mg of PGF2a per ml for intraamniotic 
injection and is indicated to induce abortion at 16-20 weeks gestation. 
(Upjohn ceased production of this product in 1988; however, stock is still 
available in various hospitals or from drug wholesalers. 10) Dinoprostone 
(PROSTIN E2) is available as a vaginal suppository containing 20 mg of 
PGE2 and is recommended for abortion at 12-20 weeks gestation.8,9,11 
Since these prostaglandins do not have a direct toxic effect on the 
unborn child, it is not uncommon for a baby to be aborted who is still alive, 
especially in later gestational ages. This has been reported as a 
"complication" of prostaglandin abortions. These live babies are either left 
to die, or are purposely suffocated. 
A recently licensed orally active synthetic analogue of PGEI , 
misoprostol (CYTOTEC, Searle) inhibits gastric acid secretion, having as 
its approved use the treatment of gastric ulcers , and as an adjunct in 
patients on long-term therapy with non-steroidal anti-inflammatory 
agents. 1213 
Natio~al pro-life groups were unsuccessful in efforts to see that 
misoprostol did not receive FDA approval for use in the U.S. These efforts 
were based on the common and serious side-effect of misoprostol to ca use a 
chemical abortion at low doses. The manufacturer of misoprostol, G. D. 
Searle, will be required to post a warning on its packaging that the drug can 
cause miscarriages when taken by pregnant women, and that physicians 
should test women for pregnancy before prescribing misoprostol. 13 
The prominence of this warning is of grave concern to the pro-life 
community due to the certainty that the drug will be used by women as a 
"do-it-yourself' abortion. It has been suggested that misoprostol will 
become a street drug because there are no other specifically abortifacient 
drugs which are effective perorally.14 With regard to the possibility of 
physicians prescribing misoprostol for the unapproved use of causing an 
abortion , a Searle spokesman has stated that there was "nothing" to 
prevent physicians from using CYTOTEC to cause an abortion , if it is 
available on the U.S. market. IS 
3. Intrauterine Devices (IUD) 
The IUD is a foreign body, usually made ofa non-reactive plastic, which 
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is inserted into the uterus for birth control purposes. Some of the devices 
are impregnated with progesterone (PROGEST ASERT, Alza) or copper 
(CU-7, Searle), which increases the efficacy of the IUD. 
It is hypothesized that there are two mechanisms by which the IUD 
prevents pregnancy. One is by alteration of sperm motility, and the other is 
by prevention of implantation of the fertilized ovum, both mechanisms 
due to a so-called "foreign body reaction," or inflammation, within the 
uterine cavity. More reports substantiate the latter mechanism of action, 
i.e. , abortifacient. The IUD does not seem to interfere with the menstrual 
cycle or ovulation. 16-18 
The IUD can cause serious complications, including, hemorrhage, 
pelvic infection, and perforation of the uterus, all having the potential to 
produce permanent sterility or death . In fact it is advised that a woman 
who may wish to bear children in the future should not use an IUD.19 
A. H . Robins, the manufacturer of an early IUD, the DALKON 
SHIELD, declared Chapter II bankruptcy in August, 1985 to protect 
itself from women seeking substantial monetary damages because of 
medical complications related to their use of the IUD. Prior to the recent 
merger of A. H. Robins with American Home Products, a federal judge 
required Robins to appropriate $100 million which would cover 
administrative costs of a "DALKON SHIELD Trust Fund", which is 
expected to grow to $2.48 billion. This fund would help compensate 
approximately 200,000 women who have filed lawsuits against A. H . 
Robins, claiming they experienced severe , and often permanent, adverse 
effects with the DALKON SHIELD.20-21 
Similarly, women using other brands of IU Ds have filed la wsuits against 
those manufacturers. G . D . Searle was recently ordered to pay $8.7 million 
in damages to a woman who suffered "infertility, illnesses, and 'great pain 
and suffering and mental anguish' " from its Copper-7 IU D. This case was 
one of 800 lawsuits filed across the U.S . relating to this product, with an 
additional 1,000 cases being previously settled . Searle was found 
"negligent" in failing to notify the Food and Drug Administration about 
what the company allegedly knew were potentially serious health risks 
with their product. Internal company memos helped to support these 
assertions.22-25 
A new copper impregnated IUD (COPPER T 380 A, ParaGard , 
GynoPharma) was introduced to the U.S. market in June , 1988.26-27 At the 
time that this IUD was introduced, the PROGEST ASERT (Alza) was the 
only IUD available in the U.S ., since other manufacturers had removed 
their IUD's from the U.S. market in 1985 and 1986 to avoid possible 
litigation. 28 Potential users of this new copper IUD will be required to sign 
a seven-page informed consent form before insertion of the IUD. Alza 
currently requires this of its PROGESTASERT users .29 
4. Oral Contraceptives ("The Pill") 
The most popular type of oral contraceptive is the combination 
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preparation which contains a synthetic estrogen and progestin. Various 
products and manufacturers are available. 3o A woman is instructed to take 
one tablet a day on days 1-21 of her cycle. On the remaining cycle days 
(22-28) the woman experiences withdrawal bleeding. 
These preparations exert their high degree of contraceptive effectivenes 
in three ways: 
1. The estrogenic component inhibits FSH (follicle stimulating 
hormone) secretion from the pituitary, while the progestin inhibits the 
release of pituitary LH (luteinizing hormone). These actions have the 
individual and combined effect of preventing ovulation.31 
2. In the woman who is taking oral contraceptives, the cervical mucus is 
thick and hostile to sperm. This is in contrast to the normal, healthy 
cycling woman whose cervical mucus is thin , watery , and abundant in 
quantity just prior to ovulation. The latter type of cervical mucus is 
conducive to longer sperm life and sperm migration, i.e., motility.32,33 
3. The third effect of combined oral contraceptives is to alter the 
endometrium in such a way that implantation of the fertilized egg (new 
life) is made more difficult, if not impossible. In effect, the endometrium 
becomes atrophic and unable to support implantation of the fertilized 
egg. 34 ,35 
At this point one may question the importance of the second and third 
actions of oral contraceptives if ovulation is inhibited. Why are these 
subsequent actions important? 
Inhibition of ovulation was nearly 100% efficient with the early oral 
contraceptives which contained a larger dose of estrogen. Reports, which 
associated the estrogen component of the preparations with serious 
thromboembolic and cardiovascular disorders , resulted in the marketing 
of the "low-dose" combination oral contraceptives. These contain a lower 
dose of estrogen. Several years of widespread use of the low-dose 
preparations have indicated that the cardiovascular risks are reduced with 
the use of the low-dose products, but they are not eliminated .35,36 
Unfortunately, the lower estrogen dose allows an increased incidence of 
breakthrough ovulation, specifically in 2-5% of cyclesY However, the 
alteration of the endometrium, making it hostile to implantation by the 
fertilized egg, provides a back-up abortifacient method to prevent 
pregnancy. This is the basis for which selected pro-life organizations object 
to the use of oral contraceptives. 
In a press release dated April 14, 198838 the U.S. Department of Health 
and Human Services announced that the three manufacturers of high-dose 
(75-100~g) , estrogen combination oral contraceptive pills had agreed to 
remove these drugs from the market. All the remaining combination oral 
contraceptives will contain a smaller dose of estrogen (30-50~g), the 
so-called "low-dose" preparations. Consequently, all currently marketed 
oral contraceptives have the potential to cause abortion as a mechanism to 
prevent pregnancy. Despite the use of low-dose combination oral 
contraceptives, breakthrough ovulation does occur, and pregnancies have 
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res ulted. 39 
A second type of oral contraceptive, which is not used to the same exetnt 
as the combination type, is the preparation which contains a progestin 
alone, the so-called "Minipill." The active ingredient is either 0.35 mg 
norethindrone (MICRONOR, Ortho; NOR-QD, Syntex) or 0.075 mg 
norgestrel (OVRETTE. Wyeth). These preparations were marketed as 
safer alternatives to the combination, estrogen-containing oral contra-
ceptives. 
The primary mechanism of action of the progestin-only oral 
contraceptives to prevent pregnancy is to cause endometrial atrophy, thus 
making i( unlikely that the fertilized egg will implant in the uterine wall. 
The quality of cervical mucus and the incidence of ovulation mayor may 
not be altered .31 ,4o,41 
The numerous risks of oral contraceptives will not be detailed here. All 
physicians and pharmacists are aware of these risks, due to the U.S. 
government requirement that a Patient Package Insert be dispensed with 
each package of birth control pills . However, recently released studies 
associate oral contraceptive use with an increased risk of breast cancer.42- 44 
A Food and Drug Administration (FDA) panel voted Jan. 5, 1989 not to 
revise the warning labels on oral contraceptives, but that further study 
would be needed on this subject. 
A contraceptive skin patch is being developed by Cygnus Research 
Corporation. The patch would deliver an estrogen and progestin for 
transdermal absorption, thus avoiding first-pass metabolism. Clinical 
trials ofthis preparation are expected in late 1989.45 Due to the lower doses 
of hormones in this investigational product, it is assumed that it will also 
have the potential to cause abortion in a small number of cycles , in a 
manner similar to the other combination oral contraceptives. 
5. Long-Acting Progestins 
Medroxyprogesterone acetate (DEPO-PROVERA, Upjohn) is the only 
product currently licensed in the U.S . in this category. A dose of 150 mg is 
injected intramuscularly once every three months. 
The FDA-authorized labeled indication for this product is to treat 
inoperable and metastatic endometrial or renal carcinoma. Due to its 
potential for causing side effects and permanent infertility, the drug is not 
authorized by the FDA as a contraceptive. However, this unlabeled use 
persists. The manufacturer of DEPO-PROVERA, Upjohn , is currently 
involved in litigation for severe side effects which allegedly occurred from 
use of this drug.46 
A preparation of levonorgestrel (NORPLANT, Wyeth) , formulated 
within six one-inch polydimethylsiloxane capsules , is currently being 
tested by the Population Council in New York for potential marketing in 
the U.S. Based on early clinical trials the drug would be administered 
subdermally through a 10 or II gauge trocar in a fan-shaped pattern into a 
3 mm skin incision. Contraceptive effectiveness would be for up to five 
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years. 47- 50 
Two preparations of long-acting progestins, in combination with 
estrogens, which are administered by intramuscular injection every two to 
six months are dihydroprogesterone acetophenide with estradiol 
enanthate (DELADROXATE, Squibb) and medroxyprogesterone acetate 
with estradiol cyprionate (CYCLOPROVERA, Upjohn). Although 
widely used in foreign countries, they are not available in the U.S. 
Other investigational injectable progestins are chlormadinone and 
norethisterone enanthate. 
The so-called vaginal rings, which contain either norethisterone, 
levonorgestrel, or progesterone in various dosage forms, release hormone 
on the days in which they are in the vagina, cycle days 5-25, after which 
time the ring is removed to allow for withdrawal bleeding.51 
One mechanism of action of long-acting progestins is to block 
implantation of the fertilized ovum, similar to the progestin-only oral 
contraceptives. 18,35 
6. Anti-Progesterones 
Anti-progesterones are a new class of investigational, so-called 
contraceptives. In reality they are abortifacients. The drugs in this class 
include mifepristone (RU 486; Roussel-Ucla£) and Epostane (Sterling) . 
Contraceptive research has turned to this type of compound in the 
search for a "once-a-month" birth control pill. The goal is to find a 
preparation which terminates pregnancy within the first five weeks after 
fertilization, but would be safer to use than combination oral 
contraceptives. For these reasons, inactivation of the corpus luteum (i .e., 
anti-progesterone) would be the preferred mechanism of action. 52 
Since mifepristone is closer to being marketed in the U. S. than 
Epostane, more detail will be devoted to it in this discussion. 
Mifepristone (RU 486) 
Acting as a competitive progesterone antagonist at the receptor leve153 ,54 
mifepristone acts to prevent the implantation of the fertilized ovum into 
the endometrium. If implantation has already occurred, the uterine lining 
deteriorates, and the baby is lost during menstruation. 
In addition to producing abortion by effecting a hostile endometrium 
for the unborn child, mifepristone softens the cervix and promotes uterine 
contractions, facilitating expulsion of the new life. 55 ,56 
Mifepristone is correctly referred to as a "contragestive" ("contra"= 
against; "-gestive"=pregnancy), i.e., abortifacient. It is intended for use 
within the first 10 weeks of pregnancy, or eight weeks after fertilization. 
Initial researchers proposed a dosage schedule of a few days every 
month. If the woman was pregnant, the baby would be aborted "naturally" 
in a menstrual period. If the woman was not pregnant, but her egg had 
been fertilized and was on its way to the uterus for implantation, 
mifepristone would cause the endometrium to become hostile to 
implantation. (Recall that progesterone is necessary for maintenance of 
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the endometrium during the time between ovulation and menstruation in 
the non-pregnant woman, and during early pregnancy in the pregnant 
woman). Mifepristone does not prevent ovulation or fertilization. 
Mifepristone was licensed for use in France and China in September, 
1988. French authorities have stipulated that abortion with this drug must 
be under the supervision of medical specialists in one of 350 hospital clinics 
to whom the drug will be distributed. 
The abortion method includes three phases. The first phase is 
administration of three-200 mg mifepristone tablets (costing the French 
equivalent of $80.00) at a clinic. One and one-half to two days later the 
woman returns to the clinic for prostaglandin administration, either by 
injection or vaginal suppository. (Reports on clinical trials in Europe have 
stated that sulprostone (Schering A. G. of Berlin, W. Germany) was the 
prostaglandin used, which produces strong uterine contractions.) The 
third phase in the abortion procedure involves a return visit to the clinic to 
verify that the embryo has been completely expelled . If the abortion was 
incomplete, a dilatation and curettage would be performed.57 - 59 
Clinical testing in the U.S. is being conducted at the University of 
Southern California (USC). Thirty women have received the combination 
of mifepristone and prostaglandin injections. These tests are described as a 
"second-stage FDA trial to determine correct dosage at different weeks of 
pregnancy. " 
The investigators at USC were reported to say that their work is being 
funded by the Population Council in New York. However, a 
representative of the Population Council was quoted as saying that past 
research on mifepristone at USC has been funded , but that the current 
work is not being funded by the Council.60 
The most serious adverse effect of mifepristone is heavy, prolonged 
bleeding, which can be as little in quantity as about three times an average 
menstrual period, lasting for two weeks, similar to an uncomplicated 
miscarriage, or can last as long as four to six weeks. A small number of 
women have required blood transfusions. 61 While this bleeding should not 
present a serious problem in the present, tightly-controlled use in France 
and China, once this drug reaches use in Third World countries , these 
controls will no longer exist. A poor woman in these countries would most 
probably receive mifepristone, and return home to her remote village, 
where medical care and availability of transfusions are absent. 
A second complication of mifepristone use it that its abortive 
effectiveness is only 80-95%. There are questions whether unborn babies 
who survive attempted abortion with mifepristone will develop normally 
throughout the remainder of their gestation, or, if the introduction of 
mifepristone by the pharmaceutical industry could make the thalidomide 
experience seem small by comparison.62 
A highly-publicized chain of events occurred in October, 1988 
concerning the manufacturer of mifepristone , Roussel-Uclaf. On Oct. 21 
the company's management committee voted to suspend distribution of 
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the drug, fearing boycotts and damage to employee morale . On Oct. 26, 
the company informed the press of its decision to remove mifepristone 
from the market, only four weeks after it had been approved for use . 
Within two days, the French Health Minister ordered Roussel-Velaf to 
reverse its decision to remove the drug, threatening the company with 
transfer of the patent for mifepristone to another company. The 
government of France owns a 36.25% financial share of Roussel-Velaf, 
and is authorized to make such transfers "for the public good." Pressured 
by this threat, and a petition of over 2000 signatures obtained at the then 
convened World Congress of Gynecology and Obstetrics in Rio de Janeiro 
opposing Roussel's decision to cease production of mifepristone, the 
company reversed its decision , and resumed distribution of the drug. 58 
Some involved in mifepristone research refer to the drug as a medical 
"menstrual regulator", which tends to mask its abortifacient mechanism of 
action. Other misleading terms , intended for the lay public , to describe 
mifepristone and other investigational abortion-causing drugs are: 
antiprogestin, contragestion, menses regulator, menses inducer, postcoital 
contraception, interceptive contraception, and post-fertilization anti-
fertility . 
Newspaper reports have indicated that sometime in the early 1990s the 
V.S. can expect marketing of mifepristone. Roussel-Velaf, however, is 
having difficulty finding an American company to shoulder the potential 
liability from introduction of this product. In an April, 1987 letter to 
Pharmacists for Life, the assistant director of the Scientific Services 
Department of Hoechst-Roussel Pharmaceuticals Inc. stated: 
In accord with our contracts , Roussel-Velaf had offered Hoeschst Roussel 
Pharmaceuticals Inc. the option for RV 486 in the V.S . We have deelined that 
option. As to whether Roussel-Velaf will license another pharmaceutical 
company to market RV 486 in the V.S., we do not know. But we can assure you 
the Hoeschst-Roussel Pharmaceuticals Inc. will not be involved with this 
compound. 
Due to the past funding of mifepristone research in the V. S. by the New 
York-based private research center, the Population Council , there have 
been reports that the drug would be marketed by a company which would 
shoulder the liability and predictable protests and boycotts by the pro-life 
community. For example, it has been stated that GynoPharma was 
created for the marketing of the Copper T 380 A I V D for the Population 
Council.63 
Similar to concerns about misoprostol, there have been concerns 
expressed about the potential "black market" for mifepristone. 64 ,65 It has 
already been reported that, under recently adopted FDA guidelines, 
mifepristone may be purchased from overseas sources for use in the V.S .66 
Epostane 
A second investigational anti-progesterone drug is Epostane. While 
both mifepristone and Epostane are anti-progesterones, their mechanisms 
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of action are different. Whereas mifepristone works at the level of the 
progesterone receptor, Epostane is a competitive inhibitor of 3beta-
hydroxysteroid dehydrogenase, the enzyme which converts pregnenolone 
to progesterone.67 ,68 
Epostane, taken perorally, has been recommended for use in 
conjunction with a prostaglandin (PGE2) vaginal suppository to cause 
abortion. Since Epostane lowers the blood levels of progesterone, thereby 
making the uterus more sensitive to the action of prostaglandins, 
investigators hope that this combination will decrease the amount of 
prostaglandin which is needed for abortion. This is "desirable" for the 
patient because the side effects of the prostaglandin, e.g., uterine pain and 
gastrointestinal upset, will be avoided. 69 
Marketing of Epostane in the U.S. does not appear imminent. Sterling 
Drug Company, the owner of Epostane, has recently been acquired by 
Eastman Kodak. In a letter to the president of Pharmacists for Life, dated 
Jan. 16, 1989, the Director of Communications for Sterling Drug Co. has 
written: 
Approximately two years ago, the Sterling Board of Directors decided that 
Epostane was not consistent with the company's goals and clinical trials were 
terminated, including any you may have seen referred (to) recently in the scientific 
or lay literature. 
Accordingly, Sterling will not develop or license this compound for human use. 
We will not supply material for clinical trials. We are not doing, nor do we intend 
to initiate, any research in this area. 
7. Abortion Vaccine 
The Task Force on Birth Control Vaccines of the World Health 
Organization Special Program of Research, Development and Research 
Training in Human Reproduction is sponsoring human testing of an 
anti-HCG vaccine. The mechanism by which this vaccine would cause 
abortion is by destruction of the hormone (HCG) which the fertilized 
ovum (unborn baby) produces to signal the corpus luteum to continue to 
produce progesterone. Again, there is seen an anti-progesterone type of 
effect, i.e. , preventing implantation of the fertilized egg into the womb. 
Sandoz Pharmaceuticals has acted as partial financier of this new 
vaccine.7o 
Conscience Clause 
Due to the marketing, and introduction, of new abortion-causing drugs, 
a serious dilemma has arisen for the pharmacy profession. Since human 
life begins when the male sperm and female ovum unite, a pharmacist who 
has convictions that destruction of this human life is wrong may find 
him-( herself unable to work as a pharmacist, without serious compromise 
of his ( her moral and ethical standards. Could a pharmacist be fired for 
refusing to dispense oral contraceptives in a retail setting, or PGF20~ in a 
hospital setting? 
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The first situation has already occurred . An April 10, 1987 article in the 
Montreal Gazette (Associated Press) carried the headline: "Two 
pharmacists fired for refusing to dispense the Pill on moral grounds." The 
pharmacists were employed at Safeway stores, and were indeed fired for 
refusing to dispense oral contraceptives. Fortunately, the two pharmacists 
have been able to gain employment at other locations, but are now 
required to commute considerable distances from their homes. 
Several pharmacists around the country who operate their own 
pharmacies have already stopped dispensing oral contraceptives. This is a 
courageous move for an independent businessman. Several of these 
pharmacy owners have sent letters to their customers explaining their 
decision. 
The 1973 Roe vs. Wade U.S. Supreme Court decision , which legalized 
abortion (throughout the entire nine months of pregnancy) in all 50 states 
was based on a purported "right to privacy". We were told that the decision 
for a woman to kill her unborn child would now be a "private" matter 
between her and her physician. 
In the 16 years , and over 24 million unborn babies killed in the U.S . 
alone, since 1973, it is evident that abortion is not private. First, those 
wanting abortions wanted others to pay for them, through health 
insurance premiums or taxes . Second, nurses in hospitals were being 
forced to assist in abortion procedures, for fear of losing their jobs. 
Likewise, medical students and residents were being coerced into 
performing abortions. In fact , some U.S. medical schools and hospitals 
required that all physicians who desired positions as obstetrical residents 
must be willing to perform abortions. The Civil Rights Restoration Act 
(Grove City), passed by the U.S. Congress in early 1988, would have also 
required all hospitals and medical schools to perform abortions if the 
institutions received any federal funds , if not for he addition of an 
amendment which was added to make the Act "abortion-neutral". 
At the present time pharmacists seem to be most at risk to lose their jobs 
for refusing to take part in abortions, when compared to other health care 
professionals . A national pro-life pharmacists' organization, Pharmacists 
for Life, has drafted the "Model Pharmacist's Conscience Clause", which 
is being submitted to professional associations , employers, and state 
pharmacy boards for possible adoption. The text of this cla use a ppears 
below: 
Any person being a dul y licensed pharmacist , who shall object on personal , 
ethical , moral or religious grounds, to the performance of any act or omission of 
any act in the normal course of professional dispensing or performance, rights of 
conscience will be respected . 
Further, such a refusal to perform any act or the omission of a ny act based 
upon such a claim of conscience, shall not form the basis of any claim for damages 
or any recriminatory or discriminatory action against such person . 
Any such person making such a claim of conscience, or who sta tes a willingness 
or intention to make such a claim of conscience , shall not be denied employment , 
or terminated from employment , or discriminated against in any manner related 
to employment because of such a claim of conscience. 
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The Center for the Rights of the Terminally III is another organization 
to recently draft a "Resolution to Protect the Rights of Conscience of 
Health Care Personnel."71 
Section 4731.91 of the Ohio Revised Code currently protects nurses, 
physicians, and institutions in their right to refuse participation in 
abortion proced ures. Onlya test court case will determine if such a la w also 
applies to registered pharmacists. 
Based on the dismissal of the two pharmacists in the state of 
Washington, pharmacists need such a conscience clause in their 
employment contracts, which will protect them from being terminated 
from their jobs for refusing to dispense drugs which kill unborn children. 
Nurses and physicians are now able to be excused from involvement in 
abortion procedures. 72 ,73 Pharmacists should have this same right. 
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3. Intrauterine Devices (IUD) 
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COPPER T 380A (ParaGard) 
A Combination lYpe (May cause abortion in a small number of cycles.) 
Estrogen Component: 




















1 Manufacturer ceased production in 1988. 
2 Not licensed in U.S.; used with mifepristone to increase complete abortion rate from 80% to 95%. 
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Oral Contraceptives 
(cont) 










































4 Investigational in U.S. Licensed in September, 1988 for use in France and China. 
S Not available in U.S. Manufacturer does not intend to market for human use. 
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